Here, we developed an ex vivo model of patient-derived tumor microexplants, namely microtumors co-cultured with autologous peripheral blood mononuclear cells (PBMCs) to screen for evidence of early response to anti-PD-1 treatment (Figure 1). This evidence concerns the gene PDCD1 and neoplasm.